How big is NanoVibronix, Inc.?

As of Jun 18, NanoVibronix, Inc. has a market capitalization of 2.33 million and reported net sales of 2.66 million with a net profit of -5.62 million over the latest four quarters. Shareholder's funds are at 0.63 million, and total assets amount to 3.63 million.

As of Jun 18, NanoVibronix, Inc. has a market capitalization of 2.33 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 2.66 million, while the sum of Net Profit for the same period is -5.62 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 0.63 million and Total Assets at 3.63 million.

What does NanoVibronix, Inc. do?

NanoVibronix, Inc. is a medical device company specializing in noninvasive devices for wound healing and pain therapy, classified as a micro-cap with a market cap of $2.33 million. As of March 2025, it reported net sales of $1 million and a net loss of $2 million.

Overview: <BR>NanoVibronix, Inc. is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2.33 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.09 <BR>Return on Equity: -14.15% <BR>Price to Book: 0.07<BR><BR>Contact Details: <BR>Address: 525 Executive Blvd, ELMSFORD NY: 10523-1240 <BR>Tel: 1 914 2333004 <BR>Website: http://www.nanovibronix.com

Should I buy, sell or hold NanoVibronix, Inc.?

Who are in the management team of NanoVibronix, Inc.?

As of March 2022, the management team of NanoVibronix, Inc. includes Chairman Christopher Fashek, CEO Brian Murphy, Chief Medical Officer Harold Jacob, Directors Martin Goldstein, Michael Ferguson, and Thomas Mika.

As of March 2022, the management team of NanoVibronix, Inc. includes the following individuals:<BR><BR>- Mr. Christopher Fashek, Chairman of the Board<BR>- Mr. Brian Murphy, Chief Executive Officer and Director<BR>- Dr. Harold Jacob, Chief Medical Officer and Director<BR>- Dr. Martin Goldstein, Director<BR>- Michael Ferguson, Independent Director<BR>- Mr. Thomas Mika, Independent Director

Is NanoVibronix, Inc. overvalued or undervalued?

As of November 15, 2021, NanoVibronix, Inc. is considered risky and overvalued due to poor financial metrics and a significant decline in stock performance, with a year-to-date return of -89.66% and a five-year decline of -99.49%.

As of 15 November 2021, the valuation grade for NanoVibronix, Inc. moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company is currently overvalued, reflected by a Price to Book Value of 0.07, an EV to EBIT of -1.16, and an EV to Sales ratio of 2.11. Compared to peers, SINTX Technologies, Inc. has a more negative EV to EBITDA of -1.2121, while Dynatronics Corp. shows a less severe EV to EBITDA of -3.1145, highlighting the relative weakness of NanoVibronix in its industry.<BR><BR>The stock has performed poorly over multiple periods, with a year-to-date return of -89.66% compared to the S&P 500's positive return of 12.22%, and a staggering decline of -99.49% over the past five years, while the S&P 500 gained 96.61%. This stark contrast in performance further reinforces the notion that NanoVibronix is overvalued given its financial metrics and market performance.

Is NanoVibronix, Inc. technically bullish or bearish?

As of August 11, 2025, NanoVibronix, Inc. exhibits a mildly bearish trend with mixed technical indicators, including bearish daily moving averages and mildly bullish weekly MACD, suggesting a lack of strong momentum.

As of 11 August 2025, the technical trend for NanoVibronix, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness, while weekly MACD and KST show mildly bullish signals. However, Bollinger Bands and Dow Theory are both indicating mildly bearish on a weekly basis. The RSI shows no signal on both weekly and monthly time frames. Overall, the mixed indicators suggest a lack of strong momentum in either direction. There is no available return data to compare the company's performance against the S&P 500.